Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047834 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
A Phase 2 study of Opioid Withdrawal (Disorder), sponsored by BioCorRx Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06047834: Active Phase 2 study of Opioid Withdrawal (Disorder), sponsored by BioCorRx Pharmaceuticals.
NCT06047834 is a Phase 2 study of Opioid Withdrawal (Disorder) that is active but no longer recruiting, run by BioCorRx Pharmaceuticals. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047834, a Phase 2 study of Opioid Withdrawal (Disorder), is active but no longer recruiting, sponsored by BioCorRx Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, described as neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS). This study has been designed to assess the pharmacokinetics (PK) and safety of the lofexidine in neonates experiencing NOWS. The effectiveness of lofexidine on the severity of NOWS will also be evaluated. Results from this study will be used to support dosing recommendations in neonates and to inform further studies in the pediatric patient population.
Primary Outcome
To evaluate the pharmacokinetic (PK) parameters of lofexidine granules for reconstitution
Conditions Studied
Interventions
- DRUG Standard of Care with Lofexidine
- OTHER Standard of Care without Lofexidine
Study Locations (1)
West Virginia
- Marshall Health - Huntington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT06047834 still lists
NCT06047834 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Opioid Withdrawal (Disorder) appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care with Lofexidine is the first listed.
NCT06047834 reports a single indexed study location in West Virginia.
Frequently Asked Questions
What is clinical trial NCT06047834 about?
NCT06047834 is a clinical study titled "Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids". A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, ...
What is the current status of trial NCT06047834?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2023-10-02. Estimated completion is 2026-10.
What conditions does trial NCT06047834 study?
This clinical trial studies the following conditions: Opioid Withdrawal (Disorder).
What interventions are being tested in trial NCT06047834?
The interventions under investigation include: Standard of Care with Lofexidine (DRUG), Standard of Care without Lofexidine (OTHER).
Who is sponsoring clinical trial NCT06047834?
This trial is sponsored by BioCorRx Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06047834 being conducted?
This trial has 1 study location across West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06047834's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI